nogron 20 mg
egis pharmaceuticals plc, maďarsko - temozolomid - 44 - cytostatica
nogron 100 mg
egis pharmaceuticals plc, maďarsko - temozolomid - 44 - cytostatica
nogron 140 mg
egis pharmaceuticals plc, maďarsko - temozolomid - 44 - cytostatica
nogron 180 mg
egis pharmaceuticals plc, maďarsko - temozolomid - 44 - cytostatica
nogron 250 mg
egis pharmaceuticals plc, maďarsko - temozolomid - 44 - cytostatica
linezolid krka 2 mg/ml infúzny roztok
krka, d.d., novo mesto, slovinsko - linezolid - 15 - antibiotica (proti mikrob. a vÍrusovÝm infekciam)
foster 200/6 mikrogramov/dávka
chiesi pharmaceuticals gmbh, rakúsko - formoterol a beklometazón - 14 - bronchodilatantia, antiasthmatica
linezolid norameda 2 mg/ml infúzny roztok
uab norameda, litva - linezolid - 15 - antibiotica (proti mikrob. a vÍrusovÝm infekciam)
linezolid kabi 2 mg/ml
fresenius kabi s.r.o., Česká republika - linezolid - 15 - antibiotica (proti mikrob. a vÍrusovÝm infekciam)
carmustine medac (previously carmustine obvius)
medac gesellschaft für klinische spezialpräparate mbh - carmustine - hodgkin disease; lymphoma, non-hodgkin - antineoplastické činidlá - carmustine is indicated n adults in the following malignant neoplasms as a single agent or in combination with other antineoplastic agents and/or other therapeutic measures (radiotherapy, surgery): , brain tumours (glioblastoma, brain-stem gliomas, medulloblastoma, astrocytoma and ependymoma), brain metastases, secondary therapy in non-hodgkin’s lymphoma and hodgkin’s disease, as conditioning treatment prior to autologous haematopoietic progenitor cell transplantation (hpct) in malignant haematological diseases (hodgkin’s disease / non-hodgkin’s lymphoma).